MDT Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 15.61% compared to Medtronic PLC's net margin of 12.41%. Medtronic PLC's return on equity of 8.56% beat Boston Scientific's return on equity of 8.96%.

Medtronic PLC has a consensus price target of $96.83, signalling upside risk potential of 16.81%. On the other hand Boston Scientific has an analysts' consensus of $115.00 which suggests that it could grow by 22.77%. Given that Boston Scientific has higher upside potential than Medtronic PLC, analysts believe Boston Scientific is more attractive than Medtronic PLC.

Medtronic PLC has a beta of 0.794, which suggesting that the stock is 20.554% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.188%.

Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.38%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Medtronic PLC quarterly revenues are $8.3B, which are larger than Boston Scientific quarterly revenues of $4.6B. Medtronic PLC's net income of $1.3B is higher than Boston Scientific's net income of $566M. Notably, Medtronic PLC's price-to-earnings ratio is 25.20x while Boston Scientific's PE ratio is 74.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.24x versus 8.31x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 15.61% compared to Medtronic PLC's net margin of 28.41%. Medtronic PLC's return on equity of 8.56% beat Intuitive Surgical's return on equity of 15.6%.

Medtronic PLC has a consensus price target of $96.83, signalling upside risk potential of 16.81%. On the other hand Intuitive Surgical has an analysts' consensus of $619.74 which suggests that it could grow by 25.56%. Given that Intuitive Surgical has higher upside potential than Medtronic PLC, analysts believe Intuitive Surgical is more attractive than Medtronic PLC.

Medtronic PLC has a beta of 0.794, which suggesting that the stock is 20.554% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.555, suggesting its more volatile than the S&P 500 by 55.506%.

Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.38%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Medtronic PLC quarterly revenues are $8.3B, which are larger than Intuitive Surgical quarterly revenues of $2.4B. Medtronic PLC's net income of $1.3B is higher than Intuitive Surgical's net income of $685.7M. Notably, Medtronic PLC's price-to-earnings ratio is 25.20x while Intuitive Surgical's PE ratio is 77.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.24x versus 21.39x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 15.61% compared to Medtronic PLC's net margin of 16.85%. Medtronic PLC's return on equity of 8.56% beat Insulet's return on equity of 43.11%.

Medtronic PLC has a consensus price target of $96.83, signalling upside risk potential of 16.81%. On the other hand Insulet has an analysts' consensus of $312.92 which suggests that it could grow by 23.2%. Given that Insulet has higher upside potential than Medtronic PLC, analysts believe Insulet is more attractive than Medtronic PLC.

Medtronic PLC has a beta of 0.794, which suggesting that the stock is 20.554% less volatile than S&P 500. In comparison Insulet has a beta of 1.300, suggesting its more volatile than the S&P 500 by 30.008%.

Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.38%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Medtronic PLC quarterly revenues are $8.3B, which are larger than Insulet quarterly revenues of $597.5M. Medtronic PLC's net income of $1.3B is higher than Insulet's net income of $100.7M. Notably, Medtronic PLC's price-to-earnings ratio is 25.20x while Insulet's PE ratio is 43.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.24x versus 9.06x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 15.61% compared to Medtronic PLC's net margin of 8.48%. Medtronic PLC's return on equity of 8.56% beat Stryker's return on equity of 15.22%.

Medtronic PLC has a consensus price target of $96.83, signalling upside risk potential of 16.81%. On the other hand Stryker has an analysts' consensus of $422.33 which suggests that it could grow by 20.57%. Given that Stryker has higher upside potential than Medtronic PLC, analysts believe Stryker is more attractive than Medtronic PLC.

Medtronic PLC has a beta of 0.794, which suggesting that the stock is 20.554% less volatile than S&P 500. In comparison Stryker has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.107%.

Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.38%. Stryker offers a yield of 0.94% to investors and pays a quarterly dividend of $0.84 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Medtronic PLC quarterly revenues are $8.3B, which are larger than Stryker quarterly revenues of $6.4B. Medtronic PLC's net income of $1.3B is higher than Stryker's net income of $546M. Notably, Medtronic PLC's price-to-earnings ratio is 25.20x while Stryker's PE ratio is 45.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.24x versus 5.98x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.